.png)
Dosing and Administration
DOSING GUIDELINES
The recommended dose of SYNAGIS is 15 mg/kg of body weight, given once a month during anticipated periods of RSV risk in the community.
Where possible, the first dose of SYNAGIS sholud be administered prior to the commencement of RSV season.1
Subsequent doses should be administered monthly throughout the RSV season.1
If a child develops or has had an RSV infection , it's important they continue to get their monthly SYNAGIS injections throughout RSV season because children can be infected by RSV more than once.1,2
Administer SYNAGIS to patients undergoing cardiopulmonary bypass as soon as possible.
Subsequent doses should be administered monthly throughout the RSV season.1
DOSING FORMULA
The exact SYNAGIS dose can be easily calculated using the following formula.1
Infant's weight (kg) x 15 mg/kg
100mg/mL
*Injection volumes over 1mL should be given as a divided dose
SYNAGIS can be administered at the same time as vaccinations and immunisations, as it is not expected to interfere with the immune response to vaccines1
HOW TO ADMINISTER
The video demonstrates the SYNAGIS indication, how SYNAGIS is supplied, dosage and how to administer SYNAGIS
IMPORTANCE OF COMPLIANCE
A full course of SYNAGIS treatment optimizes seasonal protection against RSV3
Risk of RSV-related hospitalisation doubled in high-risk infants who did not receive full-season dosing3
*Subjects were deemed compliant if they received ≥5 doses of SYNAGIS with no gaps (>35 days) between doses and received their doses by November 30 of that year.
Five repeated monthly doses of SYNAGIS maintained serum antibody levels to help provide prolonged protection against RSV4
Serum levels following a full course of SYNAGIS vs an abbreviated schedule4
Time(Days)
Simulated Concentrations-time profiles from the abbreviated 3 monthly 15-mg/kg doses of pallivizumab compared with 5 monthly doses.
Solid lines are the median Concentrations; shaded are the 95% prediction intervals.
For full safety and prescribing information, please see the SYNAGIS Summary of Product Characteristics (SmPC).
IM, intra-muscular; RSV, respiratory syncytial virus
References: 1. SYNAGIS (palivizumab). Summary of Product Characteristics. 2. Piedimonte G, Perez MK. Pediatr Rev. 2014;35(12):519-530 3. Stewart DL, et al. BMC Infect Dis. 2013;13:334. 4. Robbie GJ, et al. Antimicrob Agents Chemother. 2012;56(9):4927-4936.